• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.

作者信息

Lucijanic Marko, Krecak Ivan, Soric Ena, Sabljic Anica, Galusic Davor, Holik Hrvoje, Perisa Vlatka, Moric Peric Martina, Zekanovic Ivan, Kusec Rajko

机构信息

Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb, Croatia; University of Zagreb School of Medicine, Ul. Salata 3, 10000 Zagreb, Croatia.

Department of Internal Medicine, General Hospital Sibenik, Ul. Stjepana Radica 83, 22000 Sibenik, Croatia; University of Rijeka School of Medicine, Ul. Brace Branchetta 20/1, 51000 Rijeka, Croatia.

出版信息

Leuk Res. 2022 Aug;119:106905. doi: 10.1016/j.leukres.2022.106905. Epub 2022 Jun 21.

DOI:10.1016/j.leukres.2022.106905
PMID:35759912
Abstract
摘要

相似文献

1
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.真性红细胞增多症后骨髓纤维化患者与原发性和原发性血小板增多症后骨髓纤维化患者相比，可能会经历更高的血栓形成风险。
Leuk Res. 2022 Aug;119:106905. doi: 10.1016/j.leukres.2022.106905. Epub 2022 Jun 21.
2
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.国际预后评分系统不能准确区分原发性血小板增多症后和真性红细胞增多症后骨髓纤维化患者的不同风险类别。
Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31.
3
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.真性红细胞增多症或原发性血小板增多症转化为骨髓纤维化或急性髓系白血病患者的异基因造血干细胞移植：欧洲血液与骨髓移植组慢性恶性肿瘤工作组MPN小组委员会的报告
Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.
4
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化与原发性骨髓纤维化的预后的逐步认识。
Clin Adv Hematol Oncol. 2019 May;17(5):299-307.
5
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化的诊断标准建议：骨髓纤维化研究与治疗国际工作组的共识声明
Leukemia. 2008 Feb;22(2):437-8. doi: 10.1038/sj.leu.2404914. Epub 2007 Aug 30.
6
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型变异性与从真性红细胞增多症和原发性血小板增多症进展的时间相关。
Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23.
7
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化中的血栓形成：一项对 1258 例患者的研究。
Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30.
8
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.异基因造血干细胞移植治疗原发性血小板增多症和真性红细胞增多症后骨髓纤维化。
Intern Med. 2020;59(16):1947-1956. doi: 10.2169/internalmedicine.4375-19. Epub 2020 Aug 15.
9
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
10
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化的真实世界临床特征。
Ann Hematol. 2024 Jan;103(1):97-103. doi: 10.1007/s00277-023-05528-4. Epub 2023 Nov 10.

引用本文的文献

1
Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.明显骨髓纤维化患者的极端血小板增多症及其临床关联
Cancers (Basel). 2025 Apr 22;17(9):1390. doi: 10.3390/cancers17091390.
2
Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis.原发性和继发性骨髓纤维化中自噬标志物的基因表达分析
J Clin Med. 2025 Mar 28;14(7):2333. doi: 10.3390/jcm14072333.
3
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM).
克罗地亚慢性骨髓增殖性肿瘤临床实践调查：克罗地亚血液疾病合作组（KROHEM）MPN 工作组的一项研究
J Clin Med. 2025 Feb 24;14(5):1524. doi: 10.3390/jcm14051524.
4
No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study.脂肪性肝病对原发性血小板增多症和真性红细胞增多症患者临床结局无影响：一项初步研究。
Heliyon. 2024 Jun 11;10(12):e32827. doi: 10.1016/j.heliyon.2024.e32827. eCollection 2024 Jun 30.
5
Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.评估绝对中性粒细胞、淋巴细胞和血小板计数及其比值作为纤维化前期和明显骨髓纤维化患者血栓形成风险预测指标的价值。
Life (Basel). 2024 Apr 17;14(4):523. doi: 10.3390/life14040523.
6
Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores.真实世界电子病历数据可识别骨髓纤维化的风险因素，并可用于验证既定的预后评分。
Cancers (Basel). 2024 Apr 5;16(7):1416. doi: 10.3390/cancers16071416.
7
SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.SOHO 最新进展及未来问题探讨：真性红细胞增多症的新型治疗方法。
Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):141-148. doi: 10.1016/j.clml.2023.11.004. Epub 2023 Nov 27.
8
Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms.慢性骨髓增殖性肿瘤患者的多重用药、潜在不适当用药及药物相互作用
Biomedicines. 2023 Apr 27;11(5):1301. doi: 10.3390/biomedicines11051301.
9
Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis.更高的估计血浆体积状态与原发性骨髓纤维化患者的血栓形成风险增加和生存受损相关。
Biochem Med (Zagreb). 2023 Jun 15;33(2):020901. doi: 10.11613/BM.2023.020901. Epub 2023 Apr 15.
10
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.原发性骨髓纤维化和特发性血小板增多症的危险分层和治疗进展。
Curr Hematol Malig Rep. 2022 Oct;17(5):155-169. doi: 10.1007/s11899-022-00670-8. Epub 2022 Aug 6.